Bepotastine Besylate
The besylate salt form of bepotastine, an antihistamine eye drop used to treat itching associated with eye allergies. It acts locally in the eye to block histamine and reduce the inflammatory allergic response. It is generally well tolerated with minimal systemic absorption.
Peso molecular
547,1000 g/mol
TPSA
125,00 Ų
Áreas terapéuticas
Mecanismo de acción
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Estructura 2D
Cite this structure
Embed this structure
SMILES
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1
InChI
InChI=1S/C21H25ClN2O3.C6H6O3S/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26;7-10(8,9)6-4-2-1-3-5-6/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26);1-5H,(H,7,8,9)/t21-;/m0./s1
Molecular Formula
C27H31ClN2O6S
HBD / HBA
2 / 8
Enlaces Rotables
9
Átomos Pesados
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The besylate salt form of bepotastine, an antihistamine eye drop used to treat itching associated with eye allergies. It acts locally in the eye to block histamine and reduce the inflammatory allergic response. It is generally well tolerated with minimal systemic absorption.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Bepotastine Besylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201759. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 164521. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bepotastine-besylate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bepotastine-besylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bepotastine-besylate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bepotastine-besylate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bepotastine-besylate"></drugfyi-drug>